Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00784225 · ClinicalTrials.gov registry record · Phase 3
S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,475
- Enrollment target
NCT00784225: Completed Phase 3 study, sponsored by SWOG Cancer Research Network.
NCT00784225 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 13,475 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1648% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00784225, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,475 participants
- Enrollment target
Study Summary
RATIONALE: Aging may affect a person's vision. Vitamin E and/or selenium may help prevent cataracts or age-related macular degeneration in men receiving these drugs as part of a clinical trial for the prevention of prostate cancer. PURPOSE: This clinical trial is studying vitamin E and/or selenium to see how well they work in preventing cataract and age-related macular degeneration in men enrolled on SELECT (SWOG-S0000).
Primary Outcome
Visually significant age-related AMD was defined as incident AMD responsible for reduction in best corrected visual acuity to 20/30 or worse(AMD 20/30)
Interventions
- DRUG selenium
- DRUG vitamin E
- DRUG vitamin E placebo
- DRUG selenium placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,475 participants |
| Start Date | 2004-07 |
| Est. Completion | 2018-05 |
| Phase | Phase 3 |
What the finished NCT00784225 record still lists
NCT00784225 is an interventional study that assigns participants to a tested intervention. Its 13,475 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1648% higher).
The record links to 0 conditions, and to 4 interventions - of which selenium is the first listed.
NCT00784225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00784225 about?
NCT00784225 is a clinical study titled "S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000". RATIONALE: Aging may affect a person's vision. Vitamin E and/or selenium may help prevent cataracts or age-related macular degeneration in men receiving these drugs as part of a clinical trial for the prevention of prostate cancer. PURPOSE: This clinical trial is studying vitamin E and/or selenium ...
What is the current status of trial NCT00784225?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,475 participants. The study started on 2004-07. Estimated completion is 2018-05.
What interventions are being tested in trial NCT00784225?
The interventions under investigation include: selenium (DRUG), vitamin E (DRUG), vitamin E placebo (DRUG), selenium placebo (DRUG).
Who is sponsoring clinical trial NCT00784225?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00784225's enrollment target sits among peer trials
13,475 17th of 2000 higher than 1,984 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
- NCT07177352 · 13,000 participants · Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia